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Abstract
Context: Prolotherapy is a popular injection-based complementary treatment, which has shown promising results in the treatment
of sprained and degenerated ligaments, and damaged dense connective tissues’ structures. More research was conducted in this
area and many authors declared successful results for different indications.
Evidence Acquisition: The purpose of this study was to present a literature review regarding the current concepts of prolotherapy
injections and improvements in the orthopedic clinical care practice. The Medline and PubMed databases were searched for the
articles related to prolotherapy injections in the field of orthopedic surgery and additionally the reference list of each article was
also included to provide a comprehensive evaluation.
Results: Numerous studies have been conducted on prolotherapy injections for different indications for orthopedics clinical care
practice. Prolotherapy injections have successfully used for major orthopedic procedures in terms of rotator cuff lesions, knee liga-
mentous lesions, osteoarthritis-cartilage defects, and ligament-tendon injuries. Most of the studies showed that prolotherapy pro-
vided faster and better healing of tissues.
Conclusions: There is a great interest to prolotherapy in orthopedic clinics, especially to manage musculoskeletal lesions. More
research conducted in this area and many authors declared successful results in their studies. In spite of this increasing trend for
prolotherapy injections, there were only one or two clinical studies investigated prolotherapy injections for different indications
and most of them have limited participants, short-term follow-up or poor quality studies. There is still need for further high-quality
studies investigated optimal strategy of the injections of prolotherapy.
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1. Context
Musculoskeletal injuries are very common, and one of
the global health problems. Numerous research have been
conducted into this area; however, there is still controversy
about the most effective method (1-3).
In recently prolotherapy has successfully used in
the treatment of sprained and degenerated ligaments,
damaged dense connective tissues structures including
tendons and enthesis, chondromalacia patella and os-
teoarthritis (4-10). Too many advantages exist with this
method; including easy application, shortening the reha-
bilitation process and cost effectiveness. It also provides
healing of the structures (ligaments and tendons) then;
stability and functionality of the tissues are restored (11).
Prolotherapy injections are prepared with distinct con-
centrations of hypertonic dextrose. The solutions are in-
jected to specific regions of the effected body part, and
then provide the osmotic rupture of local cells (12). This
leads to an increase of glucose in the extracellular matrix,
which increases growth factors and causes deposition of
new collagen into different types of human cells and sub-
sequent healing (13-16).
2. Evidence Acquisition
The aim of this study was to present a systemic review
regarding the most recent progress in prolotherapy injec-
tions and current indications in orthopedic clinical care
practice. The Medline and PubMed databases (1946 to the
30th of May 2016) were searched for the articles related
with prolotherapy in the field of orthopedic surgery and
additionally the reference list of each article was also in-
cluded to provide a comprehensive evaluation.
2.1. Inclusion Criteria
In this study, English-language clinical studies (case re-
ports, case series, randomized and nonrandomized clini-
cal studies) related with prolotherapy methods in ortho-
pedic surgery were included. Every form of prolother-
apy components (e.g., dextrose or sodium morrhuate) was
included, and there was no limitation in preparing the
process of prolotherapy. Because of the lack of relevant,
matching studies, there was no limitation in comparators.
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2.2. Exclusion Criteria
Studies evaluating different treatment methods other
than prolotherapy injections, prolotherapy procedures
nonrelated with the orthopedic surgery, and nonclini-
cal study types (e.g., systemic reviews, meta-analysis, ani-
mal studies, and cadaver studies) were excluded from the
study.
The search results accounted for 135 articles. Sixty-
three articles were excluded from the study because of
nonrelevant topics, thus 72 articles were included in the
study. Thirty articles were clinical studies, 3 articles were
animal studies, and 39 articles were reviews and other
study types. The article selection process was shown in Fig-
ure 1.
Total Articles: 135
63 Articles Excluded After 
Reading Titles and Abstracts










Figure 1. Article Selection Process
3. Results
3.1. Preparation Protocols of Prolotherapy
There is no standard protocol for preparation of pro-
lotherapy solutions. Different concentrations and combi-
nations of prolotherapy solutions used in the literature
for different indications. Concentration of dextrose dif-
fers from five to twenty-five percent and the optimal con-
centration remains obscure (17, 18). Jensen K et al. (19,
20) stated that dextrose solutions below the concentra-
tion of 10% stimulate proliferation of cells and tissue but
do not have a significant effect on histological inflamma-
tory reaction with these concentrations. When dextrose
is injected in greater than the concentration of 10%, os-
motic (concentrated) gradient stimulates accumulation of
growth factors and inflammatory cells that initiates the
wound-healing cascade. Therefore, the concentrations of
dextrose greater than 10% should be preferred for prolifer-
ation and histological inflammatory reaction.
In combination with dextrose, different concentra-
tions of lidocaine, sensorcaine and xylocaine were the
most used pharmaceutical agents (20-22). There was no an-
imal or clinical study in the literature that compared the
effectiveness of different concentrations or combinations
of prolotherapy solutions (12, 19). Therefore, there is a need
for further studies investigated optimal strategy of the in-
jections of prolotherapy.
3.1.1. Number and Interval of Injection Sessions
The number and interval of injection sessions are also
different in the studies; some authors preferred single, oth-
ers preferred serial sessions, therefore number and inter-
val of injection sessions depend on experience and local
practice patterns. Prolotherapy is an invasive treatment
method and repeated injection sessions seem to be exces-
sive and costly. In the previous studies that investigated ef-
ficacy of prolotherapy in the treatment of various muscu-
losketal conditions, at least three injection sessions were
performed. Moreover, some of the studies declared that
most effective benefits could be gained with repeated in-
jections (13, 23-27).
3.1.2. Injection Procedures
Prolotherapy injections can be performed with palpa-
tion or ultrasound-guided. Chen et al. (28) compared
ultrasound-guided and palpation guided injection in the
treatment of plantar fasciitis and stated that therapeu-
tic outcomes were significantly better with ultrasound-
guided injection than palpation-guided injection. They
also stated that effectiveness and duration might increase
with the precise injections into the target points. They
also observed higher rates of recurrence with palpation-
guided injections (29). Because of the anti-inflammatory
effects, NSAIDs counteract the pro-inflammatory mecha-
nism; therefore, all NSAIDs should be stopped 2 - 3 weeks
prior to a prolotherapy procedure and then no NSAIDs
are used for the duration of treatment with prolotherapy.
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There is no consensus regarding the volume of prolother-
apy solutions. In the previous studies, 2 cc to 4 cc of pro-
lotherapy injected to every painful points (6, 8, 9, 13).
3.2. Main Indications of Prolotherapy in Orthopedic Surgery
3.2.1. Knee Osteoarthritis
Knee osteoarthritis (OA) is a chronic joint disease;
characterized by knee pain, stiffness, and functional im-
pairment. Many studies are available about efficiency
about prolotherapy injections in the treatment of os-
teoarthritis. Most of these studies have shown benefi-
cial effects of prolotherapy injections in terms of improve-
ment in pain scales (between 36% to 55% improvement)
and WOMAC subscales (30-33). Injection sites varies ac-
cording to studies; some authors were performed com-
bined intra-articular and extra-articular injection for bony
attachments of LCL or other ligaments, some preferred sin-
gle intra-articular injection. The first seemed to be more
promising method for patients with ligament injury in the
younger ages, and also elderly patients with knee OA and
have extra-articular degenerated ligaments. Mechanic in-
stability commonly occurs in patients with osteoarthritis
due to injury or degeneration of knee ligaments. The stud-
ies evaluated prolotherapy injections to the osteoarthritic
patients with traumatic knee instability have shown ben-
eficial outcomes in terms of decreasing pain and healing
knee ligaments that provide mechanic stability of knee
joint. In these studies favorable results of prolotherapy
have shown in terms of improvements of cartilage defects
and healing of extra-articular injured ligaments (22, 34).
Rabago et al. (43 investigated long-term outcomes (mean
of 2.5 years) of prolotherapy in the patients with mild-to-
severe knee OA in an open-label follow-up study. Prolother-
apy injections were resulted significant improvements in
terms of knee functions, pain intensity, and stiffness. Its ef-
fect has been shown to be better than saline injections and
pulsed radiofrequency in the randomized and controlled
studies (30, 35). No significant difference was found be-
tween prolozone and prolotherapy in a randomized clini-
cal trial (9). Also, 12.5% to 20% of dextrose concentrations
were used in the studies and success rates were similar,
thus 12.5 of dextrose may be used for osteoarthritis (8, 9,
22, 30-36). As prolotherapy is a simple, rapid, and safe op-
tion, it can be considered a first-line conservative therapy
for knee OA.
3.2.2. Chondromalacia Patella
Chondromalacia patella is one of the most common
diseases of knee accompanied by chronic pain and dys-
function. The disease is defined as the degeneration, and
thinning of the cartilage of the patella. The disease affects
both younger and older patients and if it is not properly
treated, it could be induced disruption of cartilage and
eventually resultant osteoarthritis (37). In spite of recent
treatment modalities including anti-inflammatory drugs,
exercise, physical therapy, and corticosteroid injections,
there is a need for new methods in some group patients.
Hauser et al. (10) investigated the efficiency of prolother-
apy in 61 patients with chondromalacia patella in their ret-
rospective study. They faced successful results with pro-
lotherapy injections in terms of enhancing the knee func-
tions and pain relief. Despite the aforementioned studies,
there is a need for prospective, randomized or controlled
trials in this area.
3.2.3. Epicondylitis
Epicondylitis is a common cause of elbow pain in the
middle ages. It is usually associated with repetitive and
forceful activity believed to be a degenerative process,
which stems from repetitive microtrauma (13). Prolother-
apy is thought to be promising in this area; however, a
few available studies declared contradictory results. Scar-
pone et al. (13) used prolotherapy injections in the treat-
ment of chronic lateral epicondylitis with comparison of
placebo of saline injections in a double-blind randomized
controlled trial. In the prolotherapy group, pain inten-
sity and grip strength were significantly improved up to
a mean follow-up of 50 weeks. Then Carayannopoulos et
al. (38) used prolotherapy injections with the comparison
of corticosteroid injections in the treatment of lateral epi-
condylitis in another randomized controlled trial. They ob-
served significant improvement at 3 or 6 months at both
of the groups, and there was no significant difference be-
tween the groups. There is a still need for more random-
ized controlled studies have larger participants and have
more objectively outcome measures. Most of the studies
were conducted with lateral epicondylitis, therefore the ef-
ficiency of prolotherapy is not known yet.
3.2.4. Rotator Cuff Lesions
Rotator cuff lesions are very common in all age groups
(39). A considerable number of patients can be healed with
conservative methods; however, these may not be efficient
in some group of patients, thus there is a need for new
methods in these patients (40-42). Prolotherapy injections
was firstly used by Lee et al. (43) in the nonrandomized
retrospective case-control study. They observed that pro-
lotherapy injections provide improvement in pain, disabil-
ity, isometric strength, and shoulder motion in patients
with refractory chronic rotator cuff disease resistant to
conservative treatment. Then, Bertrand et al. (44) used pro-
lotherapy in the treatment of rotator cuff tendinopathy in
a randomized and controlled study with a control group,
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which were subjected of saline injections, and observed
pain improvement and patient satisfaction, but there was
no significant difference in the shoulder pathological heal-
ing when compared to the control group.
3.2.5. Plantar Fasciitis
Plantar fasciitis is a major cause of foot disability in the
ages of 40 and 60 years (45, 46). Conservative treatment
modalities are not effective in approximately 10% of the
patients and there is a still need for more effective treat-
ment modalities for this group of patients (47). There is
limited evidence about prolotherapy in the treatment of
plantar fasciitis. In the available literature, prolotherapy
was only used by M B Ryan (48) in the treatment of chronic
plantar fasciitis of 20 patients and found a significant de-
crease in VAS scores when compared to preoperative val-
ues, and they also determined good to excellent results in
16 of 20 patients (80%). There is a need for randomized
controlled trials, which have a larger number of partici-
pants in the area. Kim et al. comprised prolotherapy and
platelet rich plasma in the treatment of chronic recalci-
trant plantar fasciitis in a single-blinded, randomized, con-
trolled study, and concluded that platelet rich plasma may
lead to a better initial improvement in function, however
all the two methods were effective and there was no signif-
icant difference between the groups (33).
3.2.6. Knee Collateral Ligaments
Collateral ligaments provide medial and lateral stabil-
ity of the knee joint. They usually injured from direct
trauma with varus and valgus stress (49). There is very lim-
ited evidence about prolotherapy in the treatment of col-
lateral ligaments. In the literature there is only a case re-
port accessed that gives evidence about prolotherapy injec-
tions in the treatment of MCL lesion of male rugby player
sustained valgus stress to his knee (50). After 12 weeks
of first prolotherapy injection he had no residual symp-
toms or functional deficit. Patient was evaluated with MRI
sixth months after trauma and the MRI findings showed
a well-healed, relatively homogeneous MCL and also sub-
chondral bone marrow edema at the corner of the lateral
tibial plateau had also diminished.
3.2.7. Osteoarthritis of Carpometacarpal or Metatarsal Joints
The symptomatic osteoarthritic hand is common over
the ages of 70 and has been estimated as 13.4% for men and
26.2% for women (51). Corticosteroid injection is the most
common method and showed benefits in the short- time
period; however, its effectiveness was stated to be tempo-
rary by many authors in the long-term (52). Azadeh Ja-
hangiri et al. (53) investigated prolotherapy in the treat-
ment of osteoarthritis of the first carpometacarpal joint
in a randomized clinical trial with comparison of corticos-
teroid injections. In the short-time (1 month), they showed
that corticosteroid injections had better outcomes than
prolotherapy. However, partial symptoms in the corticos-
teroid group were recurred in the long period (6 months)
and the prolotherapy group had significantly better out-
comes than the corticosteroid group in terms of functions
and pain after 6 months of first treatment.
3.3. Complications
Prolotherapy is known to be safe method when com-
pared to other injection based complementary methods.
The studies reported very few complications including al-
lergic reactions, superficial tissue infections and nerve
damage (12). There is no risk for tendon rupture inject-
ing in and around a tendinopathic tendon, this may occur
when the tendon insertion is too weakened. It is presumed
to be effective by stimulating weakened structures such as
ligaments and tendons to strengthen, tighten and heal by
the induced proliferation of cells (54, 55).
3.4. Limitations
Only two databases (The Medline and PubMed library)
were searched for articles; it was seemed that only the pos-
itive findings of prolotherapy were presented and coun-
terpoint articles were neglected in this review. However,
most of the included articles had positive findings about
prolotherapy injections. There may be some counterpoint
articles in the non-English literature or the other articles
indexed in other databases, leading selection bias. Screen-
ing references of identified case series and trials may result
in an over representation of positive studies in this review,
because trials with a positive result are more likely to be
referred to in other publications, leading to reference bias.
3.5. Conclusions
In recently, there is a great interest to prolotherapy in
sports medicine and orthopedic clinics, especially to man-
age chronic musculoskeletal system disorders. More re-
search conducted in this area and many authors declared
successful results. In the clinical practice its effectiveness
was firstly showed in the painful overuse tendinopathies,
by the time, it was used for osteoarthritis and successful
clinical outcomes were obtained especially in the long-
periods. In spite of new development knowledge about
prolotherapy injections, there were only one or two clin-
ical studies investigated prolotherapy injections for dif-
ferent indications and most of them have limited partici-
pants, short-term follow-up or poor quality studies. There
is still need for further high-quality studies investigated
optimal strategy of the injections of prolotherapy.
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